Andy Sutton led the way with seven hits

Anze Kopitar and Drew Doughty scored the Kings goals. Both players have had at least a point in all five Kings games.2. Kopitar's goal came on the power play. It was the first power play goal allowed by the Isles this season. They had been the only team in the NHL not to allow a power play tally, and the goal came after ten consecutive successful penalty kills by the Isles.3. Matt Moulson avoided the shutout by beating his good friend Jonathan Quick with 1:55 to play. It ended an Isles' scoreless streak totalling 87:17.And now, a few more...4. John Tavares was on ice for Moulson's goal, but was held without a point for the first time in his NHL career.5.

The Isles have now lost four consecutive games by a single goal, matching the club record, set three times previously.6. The Kings have had the Isles' number for some time now. The Isles haven't beaten the Kings at all since February 15, 2003 (three losses, a shootout loss, and a tie), and haven't beaten the Kings on Long Island since October 27, 1998 (four losses, a shootout loss, and a tie).7. The Isles out-hit Los Angeles 19-2 in the first period, and 34-22 for the game. Andy Sutton led the way with seven hits.8. The Isles are winless through four games for the first time since opening the 2000-01 season 0-3-1. It's the fourth time in their history that they have gone winless in the season's first four games (1973, 1995, 2000). The club record is seven games, held by the 1973-74 team. That team, Al Arbour's first, opened 0-3-4.10. The Isles have played a Columbus Day matinee in four of the last five seasons. They've lost four, scoring one goal in each game. The Isles are 0-5 in their history in home Columbus Day games.Up next: The Isles head to Buffalo Friday for the front-end of the season's first set of back-to-backs. The Isles were 2-1-1 against the Sabres last season.Forever1940 is the nom de plume of Eric Hornick, statistician on Islander home telecasts since 1982. Visit my blog: forever1940.blogspot and follow me on Twitter ehornick.

Publication Solely Dedicated to Advancing the Biopreservation FieldBOTHELL, Wash., Jan. 26 /PRNewswire-FirstCall/ BioLife Solutions, Inc.(OTC Bulletin Board: BLFS), a leading developer and marketer of proprietaryGMP hypothermic storage and cryopreservation media products for cells,tissues, and organs, today announced the launch of its new quarterlynewsletter BioPreservation Today, a forum for sharing knowledge aboutoptimizing biopreservation protocols and processes, to maximize the yield andfunction of cells and tissues in research and clinical applications. Burger, MD, founder of Advanced Cell &Gene Therapy, LLC, and a leading consultant to the industry, remarked on thepublication by stating, "I've been very impressed with the strides BioLife hasmade to position the company as a leading biopreservation tools provider.BioPreservation Today will be an effective vehicle to share relevant knowledgewithin the biopreservation field.Stability and yield of biological rawmaterial and cellular products, and cost per delivered dose, are criticalissues that BioLife clearly understands well, and can help hospital transplantlabs and commercial companies to overcome, via their products and consultingservices."A downloadable version of the Winter 2009 issue of BioPreservation Todaycan be found here: http:// Solutions will be presenting and exhibiting at the PhacilitateCell & Gene Therapy Forum 2009, January 26-28 in Washington, DC( http://).About BioLife Solutions, Inc.:BioLife Solutions develops and markets patented hypothermicstorage/transport and cryopreservation media products for cells, tissues, andorgans. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platformof biopreservation media products are marketed to academic researchinstitutions, hospitals, and commercial companies involved in cell therapy,tissue engineering, cord blood banking, drug discovery, and toxicologytesting.BioLife's GMP products are serum-free and protein-free, fullydefined, and pre-formulated to reduce preservation-induced, delayed-onset celldamage and death.Comprehensive small animal intravenous safety studies havebeen completed on HypoThermosol and CryoStor, and both products are supportedby US FDA Master Files.

BioLife's enabling technology provides research andclinical organizations significantly enhanced in post-preservation cell andtissue viability and function.For more information please visit http:// news release contains forward-looking statements as that term isdefined in the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements include any statements that relate to the intent,belief, plans or expectations of the Company or its management, or that arenot a statement of historical fact. Any forward-looking statements in thisnews release are based on current expectations and beliefs and are subject tonumerous risks and uncertainties that could cause actual results to differmaterially. Some of the specific factors that could cause BioLife Solutions'actual results to differ materially are discussed in the Company's recentfilings with the Securities and Exchange Commission.BioLife Solutionsdisclaims any obligation to update any forward-looking statements as a resultof developments occurring after the date of this press release Media Relations: Len Hall Allen & Caron Inc. (949) 474-4300 Investor Relations: Matt Clawson Allen & Caron Inc.